EUR 3.48
(1.93%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 95.74 Million EUR | 10.28% |
2022 | 86.81 Million EUR | 15.78% |
2021 | 74.97 Million EUR | 17.96% |
2020 | 63.56 Million EUR | 9.38% |
2019 | 58.11 Million EUR | 81.88% |
2018 | 31.95 Million EUR | 135.9% |
2017 | 13.54 Million EUR | 4.16% |
2016 | 13 Million EUR | 20.33% |
2015 | 10.8 Million EUR | 60.38% |
2014 | 6.73 Million EUR | 58.29% |
2013 | 4.25 Million EUR | 27.93% |
2012 | 3.32 Million EUR | 67.4% |
2011 | 1.98 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 108.45 Million EUR | 0.0% |
2023 FY | 95.74 Million EUR | 10.28% |
2023 Q4 | 95.74 Million EUR | 0.0% |
2023 Q2 | 94.19 Million EUR | 0.0% |
2022 Q2 | 78.83 Million EUR | 0.0% |
2022 FY | 86.81 Million EUR | 15.78% |
2022 Q4 | 86.81 Million EUR | 0.0% |
2021 Q2 | 82.48 Million EUR | 0.0% |
2021 FY | 74.97 Million EUR | 17.96% |
2021 Q4 | 74.97 Million EUR | 0.0% |
2020 Q2 | 66.95 Million EUR | 0.0% |
2020 FY | 63.56 Million EUR | 9.38% |
2020 Q4 | 63.56 Million EUR | 0.0% |
2019 Q2 | 54.57 Million EUR | 0.0% |
2019 FY | 58.11 Million EUR | 81.88% |
2019 Q4 | 58.11 Million EUR | 0.0% |
2018 FY | 31.95 Million EUR | 135.9% |
2018 Q2 | 11.57 Million EUR | 0.0% |
2018 Q4 | 31.95 Million EUR | 0.0% |
2017 FY | 13.54 Million EUR | 4.16% |
2017 Q4 | 13.54 Million EUR | 0.0% |
2017 Q2 | 11.44 Million EUR | 0.0% |
2016 Q2 | 9.62 Million EUR | 0.0% |
2016 FY | 13 Million EUR | 20.33% |
2016 Q4 | 13 Million EUR | 0.0% |
2015 FY | 10.8 Million EUR | 60.38% |
2015 Q4 | 10.8 Million EUR | 0.0% |
2015 Q2 | 8.89 Million EUR | 0.0% |
2014 Q4 | 6.73 Million EUR | 0.0% |
2014 Q2 | 4.43 Million EUR | 0.0% |
2014 FY | 6.73 Million EUR | 58.29% |
2013 Q4 | 4.25 Million EUR | 0.0% |
2013 Q2 | 3.41 Million EUR | 0.0% |
2013 FY | 4.25 Million EUR | 27.93% |
2012 FY | 3.32 Million EUR | 67.4% |
2012 Q4 | 3.32 Million EUR | 0.0% |
2011 FY | 1.98 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -1285.127% |
ABIVAX Société Anonyme | 131.05 Million EUR | 26.945% |
Adocia SA | 31.87 Million EUR | -200.408% |
Aelis Farma SA | 13.08 Million EUR | -631.957% |
Biophytis S.A. | 15.84 Million EUR | -504.076% |
Advicenne S.A. | 24.37 Million EUR | -292.747% |
genOway Société anonyme | 14.45 Million EUR | -562.125% |
IntegraGen SA | 5.97 Million EUR | -1501.058% |
Medesis Pharma S.A. | 6.42 Million EUR | -1389.842% |
Neovacs S.A. | 3.71 Million EUR | -2479.116% |
NFL Biosciences SA | 3.62 Million EUR | -2544.252% |
Plant Advanced Technologies SA | 6.78 Million EUR | -1311.605% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -2792.354% |
Sensorion SA | 13.22 Million EUR | -623.808% |
Theranexus Société Anonyme | 5.01 Million EUR | -1808.62% |
TME Pharma N.V. | 2.78 Million EUR | -3337.702% |
Valbiotis SA | 13.7 Million EUR | -598.424% |
TheraVet SA | 1.48 Million EUR | -6347.168% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -367.755% |
argenx SE | 402.79 Million EUR | 76.231% |
BioSenic S.A. | 32.26 Million EUR | -196.739% |
Celyad Oncology SA | 9.97 Million EUR | -859.511% |
DBV Technologies S.A. | 38.74 Million USD | -147.101% |
Galapagos NV | 1.56 Billion EUR | 93.87% |
Genfit S.A. | 105.92 Million EUR | 9.612% |
GeNeuro SA | 20.13 Million EUR | -375.375% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -1011.705% |
Innate Pharma S.A. | 132.29 Million EUR | 27.63% |
Inventiva S.A. | 101.59 Million EUR | 5.761% |
MaaT Pharma SA | 22.46 Million EUR | -326.174% |
MedinCell S.A. | 77.77 Million EUR | -23.107% |
Onward Medical N.V. | 25.69 Million EUR | -272.558% |
Oryzon Genomics S.A. | 25.12 Million EUR | -281.047% |
OSE Immunotherapeutics SA | 59.07 Million EUR | -62.054% |
Oxurion NV | 19.73 Million EUR | -385.103% |
Pharming Group N.V. | 228.28 Million EUR | 58.061% |
Poxel S.A. | 53.9 Million EUR | -77.622% |
GenSight Biologics S.A. | 34.72 Million EUR | -175.693% |
Transgene SA | 26.51 Million EUR | -261.051% |
Financière de Tubize SA | 123.65 Million EUR | 22.572% |
UCB SA | 6.56 Billion EUR | 98.541% |
Valneva SE | 341.14 Million EUR | 71.936% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -2005.564% |